GSK3003891A
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 02, 2019
A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women
(clinicaltrials.gov)
- P2; N=406; Completed; Sponsor: GlaxoSmithKline; Phase classification: P1/2 ➔ P2
Clinical • Phase classification
1 to 1
Of
1
Go to page
1